Claris GenomiX, a precision oncology company, has announced the licensing availability of ColoType, its patented mRNA-based Consensus Molecular Subtyping (CMS) assay. This diagnostic tool is designed to guide treatment decisions for colorectal cancer (CRC).
Key highlights from the announcement include:
- Innovative Diagnostic Tool: ColoType is the first commercially viable diagnostic capable of accurately subtyping colorectal cancer tumors based on the industry-standard CMS system.
- Potential to Improve CRC Outcomes: The tool offers hope for better outcomes in CRC patients. It could increase median survival by 30 months for over 40% of metastatic CRC patients and significantly reduce deaths in stage II and III CRC patients.
- Proprietary Technology: Developed using Claris GenomiX’s proprietary computational biology platform, ColoType offers flexibility in mRNA sequencing methods, including whole-transcriptome or custom targeted RNA-sequencing.
- Licensing and Market Introduction: The assay is available for exclusive licensing, targeting partners with established CLIA labs to bring this assay to market quickly.
- Addressing a Critical Need: With 153,000 new CRC cases expected in the United States this year and a stagnant average mortality rate, ColoType represents a significant advancement in CRC diagnostics.